• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Balkan journal of medical genetics: BJMG >DETECTING EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
【24h】

DETECTING EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

机译：检测非小细胞肺癌患者EGFR突变

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mutations in the receptor of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are used as biomarkers for predicting the response of treatment with EGFR tyrosine kinase inhibitors (EGFR TKIs). Non-small cell lung cancer patients usually have activating EGFR mutations that leads to a very good response when they are treated with EGFR TKIs. Our tumor samples were examined for the presence of sensitive mutations in the EGFR gene, resistant mutations or the absence of mutations. To identify the types of the mutation, we used a real-time polymerase chain reaction (RT-PCR) method. Additionally, we evaluated the frequency of EGFR mutations and their association with smoking status, gender and histology. The tumor samples (n = 551) were tested for 29 somatic mutations in the EGFR gene. Sensitive mutations in the EGFR genes were found in 55 NSCLC samples (10.0%). The prevalence of EGFR mutations was much higher for females than for males (27.1 vs. 3.9%, p <0.001). The prevalence of EGFR mutations was greater in subjects who had never smoked than in smokers (15.0 vs. 6.08 %,p <0.003). Additionally, the frequency of EGFR mutations was higher in adenocarcinomas than in other histological types (14.9 vs. 5.1%; p <0.001). Our results show that activating mutations on the EGFR gene are more frequent in females than in males, in adenocarcinoma than other histological types and in non smokers than smokers.
机译：非小细胞肺癌（NSCLC）中表皮生长因子受体（EGFR）的受体中的突变用作预测EGFR酪氨酸激酶抑制剂（EGFR TKI）治疗的响应的生物标志物。非小细胞肺癌患者通常具有激活EGFR突变，当它们用EGFR TKIS处理时导致非常好的反应。检查EGFR基因，抗性突变或突变的敏感突变中存在敏感突变的肿瘤样品。为了鉴定突变的类型，我们使用了实时聚合酶链反应（RT-PCR）方法。此外，我们评估了EGFR突变的频率及其与吸烟状态，性别和组织学的关联。在EGFR基因中测试肿瘤样品（n = 551）进行29个体细胞突变。在55个NMSCLC样品中发现EGFR基因中的敏感突变（10.0％）。女性的EGFR突变的患病率比男性更高，而不是男性（27.1节，3.9％，P <0.001）。在从未吸烟的受试者中，EGFR突变的患病率大于吸烟者（15.0 vs.6.08％，P <0.003）。另外，在腺癌中的EGFR突变的频率比其他组织学类型更高（14.9 vs.5.1％; P <0.001）。我们的研究结果表明，EGFR基因上的激活突变在女性中比在腺癌中更频繁，比其他组织学类型和非吸烟者比吸烟者在腺癌中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号